In its LaunchTrends® Institutional studies of Teflaro and Dificid, Arlington Medical Resources (AMR) and BioTrends Research Group surveyed 102 infectious disease (ID) specialists and internists to assess their awareness, trial, and usage of each of these products.
Date & Time
Recorded live on October 4, 2011
This webinar, presented by Arlington Medical Resources (AMR) Vice President of Research, Danielle L. Drayton, PhD, answered the following questions:
- What impact will Dificid and Teflaro have on the treatment of their respective FDA-approved indications and which currently marketed products, if any, will be most affected by the availability of Dificid and Teflaro?
- How have physicians begun to incorporate Teflaro into their treatment of ABSSSIs and CABP treatment and how is the use of the drug expected to evolve in the future?
- What is the profile of current Teflaro prescribers?
- What is the level of awareness and perception of Dificid among ID specialists and internists? How does this translate into their likelihood of using the product?
- What is the reaction of physician’s to Dificid’s profile including the drug’s efficacy and cost. How might their perceptions of Dificid impact their use of the drug for CDAD patients in the hospital and nursing home/long-term care facilities?
- What do physicians see as the key drivers and constraints on the use of Teflaro and Dificid?
This webinar was held on October 4, 2011.
Click here to access the recorded playback of this webinar.